Coulter Partners was pleased to partner recently with MiNA Therapeutics Limited (“MiNA” or the “Company”), the pioneer in small activating RNA (saRNA) therapeutics, to secure the appointments of Troels Koch, Senior Vice President, Chemistry and Ilian Tchakov, Vice President, Clinical Development.
The appointments are part of a wider expansion of MiNA’s senior leadership team to support the Company’s next phase of growth.
Troels leads MiNA’s chemistry research and strategy. He brings over 20 years of leadership in RNA therapeutics research, drug discovery and company building. Over this period Troels has established an impressive track record of identifying and championing disruptive innovations in the advancement of RNA therapeutics as a third pillar of pharmaceutical intervention. These include locked nucleic acid (LNA) chemistry, RNA chirality and computationally driven RNA drug discovery.
Most recently working as an independent consultant, Troels led RNA therapeutics research at Roche as Chief Technology Officer and VP Research, Roche Innovation Centre Copenhagen. Prior to its acquisition by Roche, Troels held the same role at Santaris where he worked for 11 years. Troels was a founder of Santaris’ predecessor companies Cureon and Exiqon which were formed around his inventions of LNA chemistry. Troels has a PhD in Bioorganic Chemistry from the University of Copenhagen.
Ilian is leading clinical development at MiNA. He has over 20 years of experience ranging from preclinical support to regulatory approval from roles at Lilly, Roche, AstraZeneca and Eisai, where he was recently Head of Oncology Global Early Clinical Development. Ilian graduated with a Medical Degree from the University of Medicine in Varna and holds a number of postgraduate degrees, including in pharmaceutical medicine from Cardiff and Oxford.
For more information about MiNA Therapeutics, please visit: www.minatx.com
Basel Healthtech Conference 2024
25 January 2024 – 26 January 2024
Coulter Partners places Board Director at IN8bio
18 May 2023
Coulter Partners secures Chair and Non-Executive Director for 2N Pharma
24 June 2021
Coulter Partners secures Chief Scientific Officer for CENTOGENE
26 February 2020